News

February 12, 2026

Affibody Medical announces outcome of rights issue

Stockholm, Sweden, February 12, 2026. Affibody Medical AB (publ) (”Affibody” or the “Company”) today announced the outcome of the Company’s rights issue of approximately SEK 307 million (the “Rights...

Read more

News

February 5, 2026

Report from Extraordinary General Meeting in Affibody Medical AB (publ)

Stockholm, Sweden, February 5, 2026. Affibody Medical AB (publ) today held an Extraordinary General Meeting. The following resolutions were adopted. The General Meeting resolved on the introduction of an...

Read more

Regulatory

January 20, 2026

Affibody Carries Out Fully Guaranteed Rights Issue of SEK 307 Million

Stockholm, Sweden, January 20, 2026. Affibody Medical AB (publ) (“Affibody”) today announced that the Board of Directors, with authorization from the annual general meeting on May 27, 2025, has...

Read more

News

January 19, 2026

NOTICE OF EXTRAORDINARY GENERAL MEETING IN AFFIBODY MEDICAL AB (PUBL)

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby invited to attend an extraordinary general meeting of the shareholders on Thursday...

Read more

Regulatory

December 16, 2025

Affibody Accelerates Phase 1 Study with ABY-271 Following Initial Patient Data

Stockholm, Sweden, December 16, 2025. Affibody AB (“Affibody”) today announced that the Trial Review Committee (TRC) has recommended to advance the Phase I clinical study with the Radioligand Therapy...

Read more

News

November 26, 2025

Affibody’s Nomination Committee for the 2026 Annual General Meeting

Stockholm, Sweden, November 26, 2025. Affibody Medical AB (publ) today announced the composition of the Nomination Committee for the 2026 Annual General Meeting (AGM) to be held on May...

Read more

Regulatory

October 24, 2025

Positive 52-week Phase 2b/3 Data of Izokibep in Psoriatic Arthritis to be Presented at ACR Convergence 2025

Solna, Sweden, October 24, 2025. Affibody AB (“Affibody”) today announced that positive 52-week data from a global Phase 2b/3 study of izokibep in psoriatic arthritis (PsA) will be presented...

Read more

Regulatory

October 21, 2025

First Patients Enrolled in Diagnostic Phase 2 Imaging Study with Affibody’s PET Imaging Agent Tezatabep Matraxetan in Metastatic Breast Cancer

Solna, Sweden, October 21, 2025. Affibody AB (“Affibody”) today announced the enrollment of the first patients in a diagnostic Phase 2 imaging study evaluating tezatabep matraxetan, the company’s PET...

Read more

Regulatory

October 7, 2025

First Patient Dosed in Phase 1 Clinical Study with Affibody’s Radiotherapeutic ABY-271 in HER2-positive Metastatic Breast Cancer

Solna, Sweden, October 7, 2025. Affibody AB (“Affibody”) today announced that the first patient has been dosed in a Phase 1 clinical study with the company’s radiotherapeutic candidate ABY-271...

Read more